loading page

Optimal Management of Severe Mpox in Patients with Uncontrolled HIV
  • Akira Shishido,
  • Stacy Street
Akira Shishido
Virginia Commonwealth University

Corresponding Author:[email protected]

Author Profile
Stacy Street
Virginia Commonwealth University
Author Profile


In May 2022, a cluster of non-travel-related cases of human mpox were reported in the UK. The outbreak has since spread world-wide infecting over 85,000 patients and causing over 100 deaths. Recent data clearly suggest that patients infected with Human Immunodeficiency Virus (HIV) with CD4 counts less than 200 cells per mm 3 suffer significantly worse outcomes than immunocompetent patients. The available countermeasures lack robust clinical data and are deployed based on in vitro and animal studies as well as extrapolations from use against other poxviruses. In many cases, despite administration of these available treatments, initiation of antiretroviral therapy, and management of Immune Reconstitution Inflammatory Syndrome (IRIS), patients die. This review summarizes available data, identifies knowledge gaps and proposes recommendations on the management of severe mpox in PLWH.
21 Sep 2023Submitted to Journal of Medical Virology
21 Sep 2023Submission Checks Completed
21 Sep 2023Assigned to Editor
21 Sep 2023Review(s) Completed, Editorial Evaluation Pending
25 Sep 2023Reviewer(s) Assigned
23 Oct 2023Editorial Decision: Revise Major
11 Nov 20231st Revision Received
11 Nov 2023Submission Checks Completed
11 Nov 2023Assigned to Editor
11 Nov 2023Review(s) Completed, Editorial Evaluation Pending
12 Nov 2023Reviewer(s) Assigned
15 Nov 2023Editorial Decision: Accept